<DOC>
	<DOCNO>NCT02447458</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics MLN3126 administer single dose tablet escalate dose level healthy participant .</brief_summary>
	<brief_title>MLN3126 Single Rising Dose Study</brief_title>
	<detailed_description>The drug test study call MLN3126 . The study evaluate safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics potential effect food PK MLN3126 M-I metabolite follow single oral dose administration . This study plan enroll approximately 48 healthy participant , enrol 1 6 dose cohort match placebo ascend fashion . Participants randomly assign MLN3126 placebo within cohort- remain undisclosed participant study doctor study ( unless urgent medical need ) : - Cohort 1 - MLN3126 300 mg match placebo - Cohort 2 - MLN3126 600 mg match placebo - Cohort 3 - MLN3126 1000 mg match placebo - Cohort 3 - MLN3126 1000 mg match placebo ( fed regimen ) - Cohort 4 - MLN3126 1500 mg match placebo - Cohort 5 - MLN3126 2000 mg match placebo - Cohort 6 - Did take place due termination study All participants ask take require tablet time throughout study . This single-centre trial conduct The United States . Participants confine clinic 5 day , contact telephone day 14 ( ±2days ) follow-up assessment . This study terminate completion Cohort 5 due finding study site non-compliance Good Clinical Practice ( GCP ) regard study documentation . There safety concern .</detailed_description>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign dated write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is male female adult , age 18 55 year , inclusive , time inform consent study drug dose . 4 . Is healthy adult male female subject evidence medical history , complete physical examination , vital sign , ECG , safety laboratory evaluation . 5 . Weighed least 45 kg ( 99 lb ) body mass index ( BMI ) 18 30.0 kg/m2 inclusive Screening . 6 . A male participant nonsterilized sexually active female partner childbearing potential agree use adequate contraception signing inform consent throughout duration study 12 week last dose . In addition , participant advise donate sperm period . 7 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study next postconfinement menstruation . In addition participant advise donate ova period . Any participant meet follow criterion qualify entry study : 1 . Has receive investigational compound within 30 day prior first dose study medication . 2 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 3 . Has uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , GI , endocrine disease abnormality , may impact ability participant participate potentially confound study result . 4 . Has know hypersensitivity component formulation MLN3126 . 5 . Has positive urine drug result drug abuse Screening Checkin ( Day 1 ) . 6 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define 4 alcoholic beverage per day ) within 1 year prior Screening visit unwilling agree abstain alcohol drug throughout study . 7 . Has take exclude medication , supplement , food product list Excluded Medications Dietary Products section protocol . 8 . If female , participant pregnant lactate intend become pregnant , intend donate ovum , , study ; include timeframe participant 's next postconfinement menstruation participate study . 9 . If male , participant intend donate sperm course study 12 week thereafter . 10 . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . There find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contra indicate take MLN3126 similar drug class , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . 11 . Has current recent ( within 6 month ) GI disease would expect influence absorption drug ( ie , history malabsorption , surgical intervention know impact absorption [ eg , bariatric surgery bowel resection ] , esophageal reflux , peptic ulcer disease , erosive esophagitis frequent [ per week ] occurrence heartburn ) . 12 . Has history cancer malignancy , except basal cell carcinoma remission least 5 year prior Day 1 . 13 . Has positive test result hepatitis B surface antigen , antibody hepatitis C virus , Screening know history human immunodeficiency virus infection . 14 . Has use nicotinecontaining product ( include , limited , cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 28 day prior Checkin Day 1 . Cotinine test positive Screening Checkin ( Day 1 ) . 15 . Has poor peripheral venous access . 16 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 45 day prior Day 1 . 17 . Has Screening Checkin ( Day 1 ) abnormal ( clinically significant ) ECG . Entry subject abnormal ( clinically significant ) ECG must approve , document signature principal investigator medically qualify subinvestigator . 18 . Has abnormal Screening Checkin ( Day 1 ) laboratory value suggest clinically significant underlying disease participant follow laboratory abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5×ULN . 19 . Has QT interval Fridericia correction method ( QTcF ) &gt; 430 m men &gt; 450 ms woman PR outside range 120 220 m confirm upon repeat test within maximum 5 minute , Screening Visit Checkin ( Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>